




# Evoluzione delle co-morbidità non infettive dopo eradicazione di HCV

Raffaele Bruno, MD












#### **EPIDEMIOLOGY**

## EDITORIAL

## NAFLD NAFLD—the next global epidemic

The future is fatty. Dramatic changes in the lifestyle and diet of the global population are fuelling a worldwide epidemic of obesity and the increasing prevalence of NAFLD. Experts now predict that the next epidemic in chronic liver disease will be a direct result of this increased incidence of obesity and NAFLD. *Nature Reviews Gastroenterology & Hepatology* therefore commissioned a special focus issue on NAFLD to provide a comprehensive overview that covers the breadth of basic, translational and clinical research on this important condition. the environment (diet in particular) and, as discussed further by <u>Wajahat Mehal</u>, the gut microbiota.

From this improved understanding in pathogenesis, it is clear that NAFLD is a complex disease, with considerable variation in severity amongst individuals. In their Review, <u>Quentin Anstee and Christopher Day</u> discuss the underlying genetics of NAFLD and argue that genetic variation might account for the heterogeneity in disease phenotype and progression. Tackling the issue of progression, <u>Anna Mae Diehl et al</u>, provide explanations as to how NAFLD-related cirrhosis can ultimately progress **44** ...NAFLD could almost be considered the human equivalent of foie gras...**77** 





Nature Reviews Gastroenterology & Hepatology 10, 621 (2013)



Sistema Socio Sanitario



### The epidemiology of non-alcoholic fatty liver disease

#### Prevalence of NAFLD in different population in Europe

|                 | Case Identification | Prevalence NAFLD           |
|-----------------|---------------------|----------------------------|
| 14 EU Countries | FLI                 | 33% (adults)               |
| Germany         | US and LE           | 2% (36% in obese children) |
| Germany         | US .                | 30% (adults)               |
| Greece          | Histology           | 31% (adults)               |
| Italy           | US                  | 26% (adults)               |
| Italy           | US                  | 12.5% (adolescents)        |
| Italy           | US                  | 44% (obese children)       |
| Italy           | US                  | 69.5% (diabetic pts)       |
| Romania         | US                  | 20% (adults)               |
| Spain           | US                  | 25.8% (adults)             |
| UK              | US                  | 46.2% (diabetic pts)       |

FLI, fatty liver index; US, ultrasound; LE, liver enzymes.




Stefano Bellentani. Liver International 2017; 37 (Suppl. 1): 81-84





NAFLD, evaluated by Fibroscan Transient Elastography with Controlled Attenuation Parameter and considering a cut off of 245 dB/m is common among HIV patients of our cohort occurring with a prevalence of 42% (54/128).








Prevalence of NAFLD in the general population and in patients with T2DM according to different diagnostic tools

The presence of T2DM significantly increases the prevalence of NAFLD in comparison of general population




Fondazione IRCCS Policlinico San Matteo

Sistema Socio Sanitario Regione Lombardia

# Prevalence of NAFLD in Patients With Type 2 diabetes and Normal Plasma AST or ALT

 The prevalence of NAFLD is higher also in overweight/obese patients with T2DM and normal aminotransferases. (N = 103)



Portillo-Sanchez. J Clin Endocrinol Metab. 2015;100:2231. Stål. World J Gastroenterol. 2015;21:11077.



#### Prevalence of NAFLD in Patients With Type 1 and 2 Diabetes




 Post hoc analysis of baseline data from 4 phase III trials (N = 589)

The prevalence of NAFLD is low in T1D patients but high in T2D patients

INIVERSITÀ DI PAVIA

 NAFLD is more frequent in insulin-naïve T2D patients compared to those previously treated with insulin









## Metabolic Consequences of NAFLD

Sistema Socio Sanitario Regione Lombardia






Cusi. Gastroenterology. 2012;142:711.





Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.

 NAFLD was associated with a worse atherogenic lipoprotein profile (LDL Particle Size Is Reduced in NAFLD), regardless of similar body mass index and other clinical parameters



Bril. J Clin Endocrinol Metab. 2016;101:644.





## Mortality Risk Associated With Isolated Steatosis and NASH

- Analysis of all-cause mortality in 6 separate studies among patients without NAFLD vs with and without NASH
- NAFLD determined by ultrasound; NASH determined by liver biopsy

UNIVERSITÀ DI PAVIA

Bril. Endocrinol Metab Clin N Am. 2016;45:765.





## Genetic Risks for NAFLD

- Known: PNPLA3, others
- Unknown:
  - Family history of diabetes, even among people without diabetes, is associated with NASH and NAFLD fibrosis<sup>[2]</sup>
  - Increased odds of advanced cirrhosis in first-degree relatives of patients with NAFLD cirrhosis<sup>[1]</sup>




1. Caussy. J Clin Invest. 2017;127:2697. 2. Loomba. Hepatology. 2012;56:943.

How to define an EUBIOTIC enterotype?

EU= good BIOS= life

Composition: Diversity
 Richness
 Relative Abundance

- Our gut is a sophisticated ecosystem that is regulated by the logic of RELATIONAL HARMONY
- Microbiota and Host live in a COOPERATIVE SYSTEMIC AGGREGATION MODEL




### Failure of HOST-MICROBIOTA equilibrium

Quali-quantitative alterations of oral, esophageal, gastric, small bowel and/or colonic microbiota



# **Gut Barrier disfunction**






#### Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease

Luca Miele,<sup>1</sup> Venanzio Valenza,<sup>2\*</sup> Giuseppe La Torre,<sup>3\*</sup> Massimo Montalto,<sup>1\*</sup> Giovanni Cammarota,<sup>1</sup> Riccardo Ricci,<sup>4</sup> Roberta Mascianà,<sup>1</sup> Alessandra Forgione,<sup>1</sup> Maria L. Gabrieli,<sup>1</sup> Germano Perotti,<sup>2</sup> Fabio M. Vecchio,<sup>4</sup> Gianlodovico Rapaccini,<sup>1</sup> Giovanni Gasbarrini,<sup>1</sup> Chris P. Day,<sup>5\*\*</sup> and Antonio Grieco<sup>1\*\*</sup>

•NAFLD in humans is associated with increased gut permeability and that his abnormality is related to the increased prevalence of SIBO in these patients.


•The increased permeability appears to be caused by disruption of intercellular tight junctions in the intestine, and it may play an important role in the pathogenesis of hepatic fat deposition



Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity

Valentina Giorgio<sup>a,1</sup>, Luca Miele<sup>b,c,1</sup>, Luigi Principessa<sup>d</sup>, Francesca Ferretti<sup>a</sup>, Maria Pia Villa<sup>d</sup>, Valentina Negro<sup>d</sup>, Antonio Grieco<sup>b</sup>, Anna Alisi<sup>a</sup>, Valerio Nobili<sup>a,\*</sup>

#### Severity of NASH and LPS in children




(HEPATOLOGY 2009;49:1877-1887.)

Digestive and Liver Disease xxx (2014) xxx-xxx


## Translocation & NAFLD

- Translocated microbial products might contribute to the pathogenesis of fatty liver disease by several mechanisms.
- Activation of Toll-like receptors (TLRs) on hepatic Kupffer cells and stellate cells to stimulate proinflammatory and profibrotic pathways via a range of cytokines.



Lipopolysaccharide signaling through the Toll-like receptors downregulates an inhibitory pseudoreceptor of TGF-β, enhancing hepatic fibrosis and liver injury

Friedman SL. Nat Med 2007 - Saki et al. Nat Med 2007




## **Microbiota in NAFLD**



### which bacteria are involved?


## At birth the human body is sterile

Vaginal microbiota (mother)



#### Gut Microbiota Profiling of Pediatric Nonalcoholic Fatty Liver Disease and Obese Patients Unveiled by an Integrated Meta-omics-Based Approach

Federica Del Chierico,<sup>1\*</sup> Valerio Nobili,<sup>2,3\*</sup> Pamela Vernocchi,<sup>1</sup> Alessandra Russo,<sup>1</sup> Cristiano De Stefanis,<sup>3</sup> Daniela Gnani,<sup>3</sup> Cesare Furlanello,<sup>4</sup> Alessandro Zandonà,<sup>4</sup> Paola Paci,<sup>5,6</sup> Giorgio Capuani,<sup>7</sup> Bruno Dallapiccola,<sup>8</sup> Alfredo Miccheli,<sup>7</sup> Anna Alisi,<sup>3</sup> and Lorenza Putignani<sup>1,9</sup>




- The combination of a low abundance of *Oscillospira* with high levels of 2-butanone may be a specific intestinal profile for liver steatosis in children.
- The high relative abundance of Lachnospiraceae, *Ruminococcus*, and *Dorea* observed in pediatric
  patients with NASH suggests that changes in the gut microbiota are associated with disease severity.

HEPATOLOGY, VOL. 00, NO. 00, 2016

#### The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota


Jérôme Boursier,<sup>1,2</sup> Olaf Mueller,<sup>3</sup> Matthieu Barret,<sup>4</sup> Mariana Machado,<sup>5</sup> Lionel Fizanne,<sup>2</sup> Felix Araujo-Perez,<sup>6</sup> Cynthia D. Guy,<sup>7</sup> Patrick C. Seed,<sup>3,6</sup> John F. Rawls,<sup>3</sup> Lawrence A. David,<sup>3</sup> Gilles Hunault,<sup>2</sup> Frédéric Oberti,<sup>1,2</sup> Paul Calès,<sup>1,2</sup> and Anna Mae Diehl<sup>5</sup>



Stratification according to the abundance of these 2 bacteria generated 3 patient subgroups with increasing severity of NAFLD lesions

#### Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

Francesca Romana Ponziani D<sup>, 1,\*</sup> Sherrie Bhoori,<sup>2</sup> Chiara Castelli,<sup>3</sup> Lorenza Putignani,<sup>4,5</sup> Licia Rivoltini,<sup>3</sup> Federica Del Chierico,<sup>4</sup> Maurizio Sanguinetti,<sup>6</sup> Daniele Morelli,<sup>7</sup> Francesco Paroni Sterbini,<sup>6</sup> Valentina Petito,<sup>1</sup> Sofia Reddel,<sup>4</sup> Riccardo Calvani,<sup>8</sup> Chiara Camisaschi,<sup>3</sup> Anna Picca,<sup>8</sup> Alessandra Tuccitto,<sup>3</sup> Antonio Gasbarrini,<sup>1</sup> Maurizio Pompili,<sup>1\*</sup> and Vincenzo Mazzaferro<sup>2\*</sup>



NAFLD cirrhotic patients have increased LPS, intestinal permeability (ZO-1), and calprotectin

 Bacteroides, Enterobacteriaceae, Ruminococcus, and

decreased abundance of *Akkermansia*, *Methanobrevibacter* and

Dehalobacterium compared to healthy controls.


Ponziani FR et al. Hepatology 2018

#### Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASH


(HEPATOLOGY 2013;57:601-609) Lixin Zhu,<sup>1</sup> Susan S. Baker,<sup>1</sup> Chelsea Gill,<sup>2</sup> Wensheng Liu,<sup>\*</sup> Razan Alkhouri,<sup>\*</sup> Robert D. Baker,<sup>\*</sup> and Steven R. Gill<sup>2</sup>

#### Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) Dig Dis Sci (2012) 57:1932–1941

Valentina Volynets · Markus A. Küper · Stefan Strahl · Ina B. Maier · Astrid Spruss · Sabine Wagnerberger · Alfred Königsrainer · Stephan C. Bischoff · Ina Bergheim




The increased abundance of alcohol-producing bacteria in NASH microbiomes, elevated blood-ethanol concentration in NASH patients, and the well-established role of alcohol metabolism in oxidative stress and, consequently, liver inflammation suggest a role for alcohol-producing microbiota in the pathogenesis of NASH




Bruno R. et al. Beyond the gut bacterial microbiota: The gut virome - Journal of Medical Virology 88:1467–1472 (2016)

#### Overview at the pathogenesis of nonalcoholic fatty liver disease (NAFLD)




(+ gut microbiota)...

Is NAFLD also an "infectious" disease?



The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD); Metabolism, volume 65, Issue 8, August 2016, Pages 1038-1048



Sistema Socio Sanitario Regione Lombardia

## Disease burden of HCC by major etiologies in the USA

NASH: 9 million Alcoholic liver disease: 3 million Alcoholic cirrhosis: 300,000 NASH-cirrhosis: 900,000 HCC incidence: 1% (~3,000) HCC incidence: 2% (~18,000) Chronic hepatitis B: 750,000 Chronic hepatitis C: 2.7 million HBV-cirrhosis:250,000 HCV-cirrhosis: 540,000 HCC incidence: 3% (~7,500) HCC incidence: 4% (~21,600) HCC Sustained nutrient excess Adipokine Adipose Obesity imbalance remodeling Insulin resistance Type 2 diabetes Hepatocellular Ectopic fat Oncogenic Isolated fatty liver accumulation pathways carcinoma Inflammation, Nonalcoholic Lipotoxicity injury,fibrosis steatohepatitis Liver remodeling Cirrhosis UNIVERSITÀ DI PAVIA


Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention




Sistema Socio Sanitario

#### NASH: Number One Indication for Liver Transplant in Patients Aged < 50 Years

Lombardia In 2015 registry of patients listed for liver transplant in US, NASH surpassed HCV infection



**Obliterative Portal Venopathy** 



Confusing terminology in presence and/or absence of PH

Schouten J et al: Hepatology 2011






# Portal Hypertension Is Classified According to the Site of Increased Resistance


| Туре                          | Example                           |
|-------------------------------|-----------------------------------|
| Pre-hepatic                   | Portal or splenic vein thrombosis |
| P <mark>re-</mark> sinusoidal | Schistosomiasis                   |
| Sinusoidal                    | Cirrhosis                         |
| Post-sinusoidal               | Veno-occlusive disease            |
| Post-hepatic                  | Budd-Chiari syndrome              |




UNIVERS<mark>ITÀ DI PAVIA</mark>





### Pre-Sinusoidal Portal Hypertension





#### **Post-Sinusoidal Portal Hypertension**








## Non-cirrhotic Portal Hypertension (NCPH)

- Maida et al. (2006) described a cohort of 17 HIV-infected patients with symptoms of portal hypertension in setting of didanosine (ddl) use
- Saifee et al. (2008) described a cohort of 11 HIV-infected patients with NCPH and correlated it to either ddl use and/or to a predisposing hypercoaguable state
- Kovari et al. (2009) conducted a nested case control study of 15 HIV-infected patients showing strong association between prolonged ddl exposure and NCPH
- Mendizabal et al. (2009) described 6 HIV-infected patients with NCPH in the setting of ddl use







#### Pathogenetic theories for NCPF/IPH.


The *Unifying hypothesis* : A major thrombotic event occuring at a young age or later in life

The *dual theory* : increased splenic blood flow + intrahepatic obstruction (obliterative venopathy)



#### Unifying hypothesis

#### Pathogenic determinants




Khan<mark>na R,</mark> J Hepatol 2014



Sistema Socio Sanitario




#### The obliterative portal venopathy 'iceberg'.




Idiopathic non-cirrhotic portal hypertension (INCPH) obliterative portal venopathy(OPV), nodular regenerative hyperplasia (NRH),



Laure Elkrief1 and Pierre-Emmanuel Rautou



#### Take Home Messages



# Si trova quello che si cerca Ma si cerca ciò che si conosce

Anonimo